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Abstract 
Pancreatic cancer is projected to become the leading cause of cancer deaths by 
2050. The risk for pancreatic cancer may be reduced by up to 27% by modifying 
lifestyle risk factors, most notably tobacco smoking. Based on analysis of more than 
2 million unselected individuals from general population, this article quantified the 
risk of pancreatic cancer in relation to lifelong tobacco smoking and alcohol 
consumption status, both alone and in combination. It also provided a state-of-the-art 
review of animal studies on the effect of tobacco smoke and alcohol on genetically 
engineered mouse models of pancreatic precursor lesions, as well as the role of 
pancreatic stellate cells and immune cells in pancreatic carcinogenesis activated by 
tobacco and alcohol. 
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Introduction 
Pancreatic cancer is the second most common gastrointestinal cancer (after 
colorectal cancer) in North America [1] and in Europe [2]. An estimated 426,000 
persons were newly diagnosed with pancreatic cancer globally in year 2015 alone 
[3]. The worldwide incidence of pancreatic cancer in the general population is 
estimated at 8.1 per 100,000 person-years [4], and is significantly higher among men 
than women (Figure 1). Further, pancreatic cancer incidence is significantly higher in 
North America than the rest of the world [4]. Given that early detection of pancreatic 
cancer in the general population is virtually impossible and taking into account the 
absence of effective therapies, prevention is currently the only way to meaningfully 
reduce the burden of this disease. Lifestyle factors markedly affect the risk of 
pancreatic cancer and it was estimated that more than a quarter of pancreatic cancer 
cases may have been prevented if all people in the general population were non-
smokers and had limited alcohol consumption, healthy diet, normal weight, and 
regular physical activity [5].  
 
Tobacco smoking and alcohol consumption are the second and third leading risk 
factors of death globally, according to a study estimating the disease burden 
attributable to 43 risk factors in 2010 [6]. The global prevalence of current tobacco 
smoking was estimated to be 36% in males and 7% in females in 2015 [7]. Although 
prevalence of smoking has decreased considerably across the world in both low-to-
middle income countries and in high-income countries (except in African and Eastern 
Mediterranean regions) [8], absolute number of smokers have increased with nearly 
one billion daily smokers worldwide in 2012. Global prevalence of heavy episodic 
drinking among persons 15 years and older is estimated at 7.5% (16% of drinkers), 
while prevalence of abstinence (no alcoholic drink within 12 months) was estimated 
at 62% [9]. Further, estimates for heavy episodic drinking were higher in Europe 
(17%) and the Americas (14%) as compared with less than 2% in the Eastern 
Mediterranean and South East Asian regions. Unlike smoking trends, alcohol 
consumption has not changed drastically in recent decades. Globally alcohol 
consumption has increased on average from 2005 to 2010, although decreases in 
consumption in certain Asian and African countries have been noted [9]. 
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In the context of pancreatic cancer, tobacco smoking is considered the most 
important risk factor [10], with population attributable risk of 14%, and alcohol 
consumption is the fourth most important risk factor, with population attributable risk 
of 3% [5]. Further, given that smoking behaviour is often associated with alcohol 
consumption, it is plausible that there is effect modification between smoking and 
alcohol in affecting the risk of pancreatic cancer [10]. 
 
It should be noted that pancreatic cancer is an umbrella term that includes several 
malignancies. About 90% of these cancers are pancreatic ductal adenocarcinomas 
(PDACs). The most common precursor lesions to PDAC are pancreatic intra-
epithelial neoplasia (PanIN) that progress from stage IA to stage III and ultimately to 
PDAC [11]. PanIN arise from acinar to ductal metaplasia (ADM) lesions [11], and 
stage I-II PanIN may occur in patients who never develop PDAC. By contrast, stage 
III PanIN lesions have a high propensity to become PDAC. Importantly, 90 to 95% of 
PDAC harbor a mutated KRAS, and this mutation is the major contributor to PDAC 
initiation [12], progression and metastasis [13,14]. 
 
Critique of study designs of tobacco, alcohol and risk for pancreatic cancer 
Multiple studies have reported on associations between tobacco smoking and risk of 
pancreatic cancer as well as alcohol consumption and risk of pancreatic cancer. 
However, their findings must be interpreted with caution because study designs were 
often suboptimal to investigate the associations between exposure to smoking 
and/or alcohol and subsequent risk of pancreatic cancer [10]. In particular, case-
control studies should be interpreted with caution. They are frequently used because 
this study design requires considerably less time and funding to achieve adequate 
statistical power than a prospective cohort study. However, given late diagnosis and 
dismal prognosis of pancreatic cancer, majority of individuals become physically 
unable to participate in epidemiological studies or pass away before they can be 
interviewed regarding exposure factors. This violates the fundamental assumption of 
the case-control design, i.e. that the selected cases and controls must unbiasedly 
represent the underlying cohort. The other common problem with case-control 
studies is survivor bias, which occurs when the exposure (specifically, tobacco 
smoking and/or alcohol consumption) and the outcome (specifically, incidence of 
pancreatic cancer) are conditionally associated with survival time. Case losses in 
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pancreatic cancer case-control studies could therefore introduce survivor bias and 
lead to a significant deviation in statistical estimates from the true associations in the 
general population [15]. For example, given that smoking is associated with shorter 
mortality in general, survivor bias could potentially underestimate the prevalence of 
smoking in pancreatic cancer cases. Also, recall bias is another common problem 
with investigations on smoking and alcohol, in particular retrospective studies, 
because cases tend to recall past exposures differently than control do [16]. 
Epidemiologic research on risk factors for pancreatic cancer that is conducted on 
special cohorts (e.g., veterans only, nurses only, insurance claims) may introduce a 
selection bias and, hence, may not be generalisable [17]. Cohort studies in general 
population is arguably the best available study design but also have limitations 
as they require extremely long follow-up before enough pancreatic cancer cases 
have accrued, during which time alcohol consumption and tobacco smoking habits 
may have changed. 
 
Exposure to tobacco and alcohol and risk for pancreatic cancer in general 
population 
To provide the most robust quantifiable data on the effect of smoking and alcohol on 
risk of pancreatic cancer, we conducted a literature search in PubMed for articles 
published between January 1, 2000, and July 1, 2017. The inclusion criteria were all 
of the following: 
- study design: prospective, population-based, cohort studies;  
- study population: adult individuals of both sexes in a given geographic area in 
a given period of time; 
- exposure: tobacco smoking and/or alcohol consumption 
- outcome: incident case of pancreatic cancer 
Studies were excluded if: 
- they were retrospective cohort, (nested) case-control, cross-sectional, or 
interventional studies; or 
- study population was not representative of the general population (e.g., 
cohorts constrained to 1 gender only or a particular ethnicity; insurance 
claims, secondary or tertiary settings); or 
- small sample size, arbitrarily defined as the total size of the cohort of less than 
25,000 or 
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- they were conducted in animals; or 
- risk of developing pancreatic cancer was not reported, and/or it was not 
possible to reconstruct a 2x2 contingency table and meta-analyze data. 
If tobacco smoking or alcohol consumption was investigated in more than 1 study 
derived from the same cohort, the study with the most complete information on either 
of the exposures was selected. StatsDirect was used to generate forest plots and 
pooled relative risks (RR) with corresponding 95% confidence intervals (CI). Data 
were statistically aggregated using the DerSimonian-Laird random-effects model to 
account for potential random variation of associations between study populations. 
 
A total of 12 prospective, population-based, cohort studies met all the eligibility 
criteria [18-29]. Of them, 11 investigated smoking as risk factor for pancreatic 
cancer, 5 – alcohol as risk factor for pancreatic cancer, and 3 - interaction of 
smoking with alcohol as risk for pancreatic cancer (Table 1). 
 
Smoking as risk factor for pancreatic cancer 
Ten of the eligible studies were suitable for meta-analysis of smoking as risk factor 
for pancreatic cancer. In the pooled cohort, a total of 366,653 individuals were 
current smokers, 361,944 – former smokers, and 675,400 – never smokers. Current 
smokers had the pooled RR of 1.66 (95% CI 1.38 to 1.98) when compared with 
never smokers (p < 0.05), and the pooled RR of 1.18 (95% CI 1.00 to 1.38) when 
compared with former smokers (p < 0.05)..Former smokers had the pooled RR of 
1.40 (95% CI 1.16 to 1.67) when compared with never smokers (p < 0.05). Figure 2 
details the pair-wise comparisons between the 3 studied subgroups. Statistical 
heterogeneity (as eveidenced by I² metric) was 70%, 47%, and 63%, 
correspondingly. 
 
Alcohol as risk factor for pancreatic cancer 
Two of the eligible studies were suitable for meta-analysis of smoking as risk factor 
for pancreatic cancer. In the pooled cohort, a total of 133,213 individuals were heavy 
drinkers, 685,428 – light drinkers, and 682,497 – never drinkers. Heavy drinkers had 
the pooled RR of 1.29 (95% CI 1.20 to 1.38) when compared with never drinkers (p < 
0.05), and the pooled RR of 1.36 (95% CI 1.02 to 1.80) when compared with light 
drinkers (p < 0.05). Light drinkers had the pooled RR of 0.96 (95% CI 0.75 to 1.22) 
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when compared with never drinkers. Figure 3 details the pair-wise comparisons 
between the 3 studied subgroups. Statistical heterogeneity (as eveidenced by I² 
metric) was 28%, 87%, and 91%, correspondingly. 
 
Interaction of smoking with alcohol as risk for pancreatic cancer 
Three prospective, population-based, cohort studies investigated interaction between 
smoking and alcohol as risk factor for pancreatic cancer but none was suitable for 
meta-analysis. The study by Jiao et al. [24] followed up a total of 450,416 individuals 
in the USA (who originally resided in 1 of 6 states - California, Florida, Louisiana, 
New Jersey, North Carolina, and Pennsylvania) who reported servings of alcohol use 
per day for total beverages and stratified their analysis by smoking status. One 
serving (1 drink) was defined on the basis of the US Department of Agriculture’s 
Food Guide Pyramid as 12 fluid ounces of regular beer (12.96 g of alcohol), 5 fluid 
ounces of wine (13.72 g of alcohol), or 1.5 ounces of 80 proof distilled spirits liquor 
(13.93 g of alcohol). In multivariate analysis (adjusted for sex, total energy intake, 
energy-adjusted saturated fat, red meat, and total folate intake, body mass index, 
physical activity, and history of diabetes), the authors found a statistically significant 
increase in the risk of pancreatic cancer among ever smokers, but not never 
smokers. Compared with that for light use (i.e. less than 1 drink per day), the relative 
risk for heavy total alcohol use (i.e. at least 3 drinks per day) was 1.50 (95% CI 1.18 
to 1.90) in ever smokers. Specifically, the relative risk was 1.54 (95% CI: 1.11 to 
2.13) in current smokers and recent quitters and 1.41 (95% CI 1.01 to 2.00) in those 
who quit at least 10 years ago. Compared with that for light use, the relative risk for 
heavy total alcohol use was 1.35 (95% CI 0.79 to 2.30) in never smokers. There 
were no statistically significant interactions of alcohol use on risk of pancreatic 
cancer by smoking status (p interaction = 0.25) or the number of years since quit 
smoking (p interaction = 0.61). 
 
The study by Johansen et al. [25] followed up a total of 33,346 individuals in Sweden 
who reported a modified version of the Michigan Alcoholism Screening Test (which 
contained 7 questions regarding drinking habits but no questions on absolute 
amounts of alcohol intake). In multivariate analysis (adjusted for age, sex, body 
mass index), the authors found a statistically significant increase in the risk of 
pancreatic cancer among former smokers, but not never smokers or current 
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smokers. Compared with that for low alcohol consumption (i.e. score 0-1), the 
relative risk for intermediate or heavy alcohol consumption (i.e. score 2 or above) 
was 2.13 (95% CI 1.05 to 4.32) in former smokers; 1.39 (95% CI 0.91 to 2.12) in 
current smokers; and 1.31 (95% CI 0.63 to 2.72) in never smokers. There was no 
statistically significant interaction of alcohol use on risk of pancreatic cancer by 
smoking status (p interaction = 0.29). 
 
The study by Gapstur et al. [26] followed up a total of 1,030,467 individuals in the 
USA (who came from all the US states, the District of Columbia, and Puerto Rico) 
who completed a questionnaire detailing absolute amounts of alcohol intake. In 
multivariate analysis (adjusted for age, sex, ethnicity, education, marital status, body 
mass index, family history of pancreatic cancer, and personal history of gallstones 
and diabetes mellitus), the authors found a statistically significant increase in the risk 
of pancreatic cancer among both ever smokers and never smokers. Compared with 
that for non-drinkers, the relative risk for heavy alcohol consumption (i.e. at least 3 
drinks per day) was 1.36 (95% CI 1.13 to 1.62) in never smokers and 1.22 (95% CI 
1.12 to 1.34) in ever smokers. In further subgroup analyses, the combined effect of 
smoking and alcohol on risk of pancreatic cancer remained statistically significant 
only in those ever smokers who reported heavy consumption of liquor (relative risk 
1.18; 95% CI 1.03 to 1.35) but not beer (relative risk 1.08; 95% CI 0.92 to 1.26) or 
wine (relative risk 0.98; 95% CI 0.76 to 1.26). There was no statistically significant 
interaction of alcohol use on risk of pancreatic cancer by smoking status (p 
interaction = 0.58). 
 
Mechanisms of effects of tobacco and alcohol 
Given that pancreas is one of the least accessible organs and taking into account 
that pancreatic tissues are rarely availble for studies, mechanisms of effects of 
tobacco and alcohol has been maiinly investigated in animal studies [30-34]. 
Administration of tobacco to healthy rodents does not cause pancreatic cancer in 
rats. Nonetheless, rats exposed for four months to daily cigarette smoke exhibit 
acinar cell loss, increased pancreatic matrix deposition and infiltration of the 
pancreas with CD45-positive immune cells [35]. Importantly, CD45 is a receptor-like 
tyrosine phosphatase that is crucial for proper B and T cell function [36], highlighting 
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the ability of tobacco smoke tobacco smoke to alter the immune microenvironment 
within the pancreas.  
 
The effects of cigarette smoke have also been examined in genetically engineered 
mouse models (GEMMs) of PDAC. The most studied model in this regard consists of 
mice designed to express the oncogenic Kas protein in the pancreas (termed KC 
mice) [30]. These studies revealed that that tobacco exerts dramatic effects in the 
pancreas. Thus, exposure of KC mice to cigarette smoke (for 20 weeks) enhances 
ADM formation and accelerates PanIN development in conjunction with decreased 
number of myeloid-derived suppressor cells (MDSCs) and an increase in the number 
of M2 macrophages and dendritic cells in the pancreas [37], underscoring the 
deleterious effects of cigarette smoke on the immune system in the pancreatic 
microenvironment that has already been compromised by the expression of 
oncogenic Kras.  
 
The trans-differentiation of acinar cells to ADM precursor lesions requires the loss of 
acinar cell identity, and the latter is dictated by expression of several transcription 
factors including Gata6, Mist1, and PTf1 [38,39]. When administered prior to tumor 
formation, nicotine accelerates PDAC formation in several types of GEMMs due to 
the activation of an AKT-ERK-MYC signaling cascade that promotes ADM formation  
by decreasing Gata6 expression and inducing acinar cell de-differentiation [40]. In 
these GEMMs, when nicotine is administered once PDAC is established, there is 
enhanced epithelial–mesenchymal transition (EMT) and a greater propensity to form 
hepatic metastases. Moreover, in KC mice, exposure to cigarette smoke promotes 
PanIN and stroma formation, EMT, and appearance of M2 macrophages, and these 
effects can be reversed by the HDAC inhibitor suberoylanilide hydroxamic acid 
(SAHA), in agreement with the ability of cigarette smoke to decrease histone 
acetylation [41]. Taken together, the above studies support the concept that 
prolonged exposure to tobacco smoke over many years, as seen in humans, can 
lead to pancreatic malignant transformation. 
 
As in the case of tobacco, alcohol per se has not been shown to cause neoplastic 
transformation in the rodent pancreas. However, alcohol was shown to promote an 
increase in the number of M2 macrophages within PDAC in the KC GEMM, and to 
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slightly enhance fibrosis [42]. This is an important observation since M2 
macrophages promote cancer progression by suppressing cancer directed immune 
mechanisms and impeding T cell recruitment into the tumor [43]. Moreover, caerulein 
causes stellate cell activation and contributes to PDAC fibrosis, but also induces 
histone deacetylation, and this latter effect is enhanced by alcohol [42]. Histone 
deacetylation represses gene transcription and may promote loss of tumor 
suppressor gene functions.  
 
Present challenges and future directions 
1. Cessation of smoking for 10 or more years returns the relative risk of 
pancreatic cancer to levels equivalent to non-smoker [44,45]. However, 
communication to the public of the harmful effect of tobacco smoking and the 
beneficial effect of quitting is poor. In this regard, rate advancement periods is 
a useful statistic for lay people. A recent study showed that being a current 
smoker (compared with never smoking) increases the risk of developing 
pancreatic cancer by more than 7 years [46]. Quitting smoking within 10 years 
(compared with not quitting) delays the risk of development of pancreatic 
cancer by more than 3 years; within 20 years – by more than 5 years; and 
quitting for more than 20 years – by more than 10 years [46]. 
2. Studies on associations between alcohol consumption and risk for pancreatic 
cancer have largely focused on average drinking over lifetime or drinking at 
baseline or recent drinking [47], but it is unknown how changes in alcohol 
consumption during the follow-up period (in particular, cessation of drinking 
and drinking during adolescence/young adulthood) is associated with risk for 
pancreatic cancer. Given that alcohol cessation leads to reductions in risk of 
recurrent acute pancreatitis [48] and taking into account the recurrent acute 
pancreatitis-chronic pancreatitis-pancreatic cancer continuum [49,50], future 
studies should investigate whether alcohol cessation also reduces the risk of 
pancreatic cancer. 
3. Little is known about the direct effects of tobacco products and their 
metabolites on pancreatic stellate cells activation and secretion. Considering 
the evidence presented above, it would be very useful to determine how these 
compounds could regulate pancreatic stellate cells and contribute to the 
microenvironment within the pancreas [32,34]. 
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4. Most studies published to date assumed additivity between average effects of 
tobacco and alcohol, and hence oversimplified their impact on burden of 
pancreatic cancer. Carefully designed modelling studies on hypothetical 
changes in lifestyle risk factors at the population-level are warranted to 
examine the interactions between smoking, alcohol (and metabolic conditions 
such adiposity and diabetes [51,52]) and their impact on burden of pancreatic 
cancer. Such studies will need to be large enough to detect multiplicative 
interaction between tobacco, alcohol (and metabolic factors) and have 
sufficient number of cases for pancreatic cancer in each permutation risk 
factors. 
5. To date, high quality population-based studies on tobacco and alcohol as risk 
factors for pancreatic cancer have almost invariably come from only 3 
countries – USA, Japan, and Sweden. Studies from other part of the world 
would greatly enrich the knowledge on these relationships and should be 
viewed favorably by funding agencies [4,10]. 
6. Large prospective cohort studies of individuals at high risk of pancreatic 
cancer, such as patients with pancreatitis or diabetes of the exocrine 
pancreas [53-55], will provide opportunities to accurately measure exposure to 
smoking and alcohol in a standardized manner and allow for an analysis of 
the synergistic impact of alcohol and smoking, as well as metabolic disorders. 
 
Summary 
The last two decades have witnessed the appearance of large population-based 
studies that established tobacco smoking as the strongest modifiable risk factor for 
pancreatic cancer. This opens up real opportunities for primary prevention. Progress 
has been slow and difficult for understanding the molecular pathogenesis of 
pancreatic cancer. However, GEMMs including lifestyle risk factors such as tobacco 
and alcohol are positioned well to provide deeper insights into the complex interplay 
between the microenvironment and the cancer cells, which may lead to important 
discoveries of drugs that target molecular pathways that are activated by tobacco 
and alcohol. 
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Practice Points 
• A large body of evidence consistently demonstrates that tobacco smoking 
status is significantly associated with risk of developing pancreatic cancer in 
general population 
• Current smokers have a 66% higher risk of pancreatic cancer and former 
smokers have a 40% higher risk of pancreatic cancer in comparison with 
never smokers 
• A limited body of evidence shows that alcohol consumption status may be 
associated with risk of developing pancreatic cancer but findings of 
population-based studies are inconsistent 
• The combined effect of smoking and total alcohol on risk of pancreatic cancer 
is likely to be non-additive; as an example only heavy consumption of liquor, 
but not wine or beer, increases the risk of pancreatic cancer in ever smokers 
 
 
Research Agenda 
• The recurrent acute pancreatitis-chronic pancreatitis-pancreatic cancer 
continuum is a valuable framework to adopt in future studies on pathogenesis 
of pancreatic cancer 
• Time since smoking cessation, smoking intensity, and duration need to be 
investigated as comprehensively as lifelong smoking status 
• Adequately powered epidemiological studies are warranted to examine the 
association between alcohol consumption and risk for pancreatic cancer by 
tobacco smoking status, most pressingly in lifelong never smokers 
• Given that incidence of pancreatic cancer in general population is low, 
(inter)national consortiums will help achieve the sample size needed 
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Figure Legends 
 
Figure 1. Estimated incidence of pancreatic cancer mortality worldwide in 2012 
among men (A) and women (B) according to data from the International Agency for 
Research on Cancer 
 
Figure 2. Tobacco smoking status and risk factor for pancreatic cancer: (A) current 
smokers versus never smokers, (B) former smokers versus never smokers, and (C) 
current smokers versus former smokers 
 
Figure 3. Alcohol consumption and risk factor for pancreatic cancer: (A) heavy 
drinkers versus never drinkers, (B) light drinkers versus never drinkers, and (C) 
heavy drinkers versus light drinkers 
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Table 1. Characteristics of the included studies 
Study ID Country Total 
cohort 
size 
No of 
pancreatic 
cancer 
cases 
Risk factor Suitable for meta-analysis 
Smoking Alcohol Both Smoking Alcohol Both 
Gapstur et 
al., 2000 [18] 
USA 35,658 139 Yes No No Yes No No 
Lin et al., 
2002 [19] 
Japan 110,792 225 Yes No No Yes No No 
Larsson et 
al., 2005 [20] 
Sweden 83,506 131 Yes No No Yes No No 
Gallicchio et 
al., 2006 [21] 
USA 48,172 92 Yes No No Yes No No 
Luo et al., 
2007 [22] 
Japan 99,670 224 Yes Yes No Yes No No 
Arnold et al., 
2009 [23] 
USA 1,060,389 6,243 Yes No No Yes No No 
Jiao et al., 
2009 [24] 
USA 450,416 1,057 Yes Yes Yes No Yes No 
Johansen et 
al., 2009 [25] 
Sweden 33,346 183 Yes Yes Yes Yes No No 
Gapstur et 
al., 2011 [26] 
USA 1,030,467 6,847 No Yes Yes No Yes No 
Nakamura et 
al., 2011 [27] 
Japan 30,826 52 Yes Yes No Yes No No 
Meyer et al, 
2015 [28] 
Switzerland 35,784 127 Yes No No Yes No No 
Andersson et 
al., 2016 [29] 
Sweden 28,098 163 Yes No No Yes No No 
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Figure 1. Estimated incidence of pancreatic cancer mortality worldwide in 2012 
among men (A) and women (B) according to data from the International Agency for 
Research on Cancer 
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Figure 2. Tobacco smoking status and risk factor for pancreatic cancer: (A) 
current smokers versus never smokers, (B) former smokers versus never 
smokers, and (C) current smokers versus former smokers 
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Figure 3. Alcohol consumption and risk factor for pancreatic cancer: (A) heavy 
drinkers versus never drinkers, (B) light drinkers versus never drinkers, and (C) 
heavy drinkers versus light drinkers 
 
